The collaboration will leverage proprietary stem cell lines developed by Medistem to screen monoclonal antibodies for therapeutic activity in the area of regenerative medicine.
Medistem CEO Thomas Ichim said the collaboration with Superview Biotechnology aims to assess the feasibility of developing antibodies that can modulate the activity of stem cells that already exist in the body.
"This approach not only provides methods of activating stem cells but also allows for the development of stem cell adjuvant therapies that could be used to resurrect stem cell candidates that failed in clinical trials," Ichim added.
Under the collaboration, the companies will jointly evaluate various candidates, in addition to applying for grants and share research data.
A joint grant is likely to be filed with the National Natural Science Foundation of China to support part of the proposed collaboration by end of October 2012.